Literature DB >> 28500114

Pseudoprogression in lung adenocarcinoma during treatment with nivolumab.

Toshihide Izumida1, Yukio Kawagishi1, Hiroshi Tsuji1.   

Abstract

Entities:  

Keywords:  Lung cancer (oncology); Oncology

Mesh:

Substances:

Year:  2017        PMID: 28500114      PMCID: PMC5614138          DOI: 10.1136/bcr-2017-219919

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


× No keyword cloud information.
  6 in total

1.  Expectoration of tonsillar metastasis of pulmonary pleomorphic carcinoma after pseudoprogression: A case report.

Authors:  Tomoki Kuge; Fukuko Okabe; Yuji Yamamoto; Mikako Ishijima; Takeshi Uenami; Masaki Kanazu; Yuki Akazawa; Yukihiro Yano; Toshihiko Yamaguchi; Masahide Mori
Journal:  Thorac Cancer       Date:  2021-05-11       Impact factor: 3.500

2.  Patterns of response in metastatic NSCLC during PD-1 or PD-L1 inhibitor therapy: Comparison of the RECIST 1.1 and iRECIST criteria.

Authors:  Hongge Liang; Yan Xu; Minjiang Chen; Wei Zhong; Mengzhao Wang; Jing Zhao
Journal:  Thorac Cancer       Date:  2020-03-04       Impact factor: 3.500

3.  A Multimodal Approach to Evaluate for Cardiac Metastasis in a Case of Non-Small Cell Lung Cancer.

Authors:  Nadeem Bilani; Leah Elson; Felipe Martinez; Diego Sadler; Zeina Nahleh; Elizabeth Elimimian; Evan Alley
Journal:  Case Rep Oncol       Date:  2020-03-05

4.  Immune RECIST criteria and symptomatic pseudoprogression in non-small cell lung cancer patients treated with immunotherapy.

Authors:  Martina Vrankar; Mojca Unk
Journal:  Radiol Oncol       Date:  2018-10-18       Impact factor: 2.991

Review 5.  How Can Immune Checkpoint Inhibitors Cause Hyperprogression in Solid Tumors?

Authors:  Morgane Denis; Michael Duruisseaux; Marie Brevet; Charles Dumontet
Journal:  Front Immunol       Date:  2020-03-20       Impact factor: 7.561

6.  The potential mechanism, recognition and clinical significance of tumor pseudoprogression after immunotherapy.

Authors:  Wenxiao Jia; Qianqian Gao; Anqin Han; Hui Zhu; Jinming Yu
Journal:  Cancer Biol Med       Date:  2019-11       Impact factor: 4.248

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.